The clinical patterns of vitiligo "hospital-based study" in Makkah region, Saudi Arabia

被引:12
作者
Fatani, M. I. [1 ]
AlSharif, S. H. [2 ]
Alfif, K. A. [1 ]
Khan, A. S. [1 ]
Hussain, W. A. [1 ]
Banjar, A. A. [1 ]
机构
[1] Hera Gen Hosp, POB 5970,, Mecca 21955, Saudi Arabia
[2] Umm AlQura Univ, Mecca, Saudi Arabia
来源
JOURNAL OF DERMATOLOGY DERMATOLOGIC SURGERY-JDDS | 2014年 / 18卷 / 1-2期
关键词
Vitiligo; Saudi Arabia; Makkah;
D O I
10.1016/j.jssdds.2013.12.001
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Little is known about the clinical patterns of vitiligo and its associations in Arab countries, particularly Saudi Arabia. Methods: We performed a retrospective review of 135 medical records of patient with vitiligo seen at the Hera Hospital, Makkah, Saudi Arabia between January 2010 and June 2013. Results: Of the 135 patients (mean age, 24.5 years), 91 (67.4%) were females. Twenty-six patients (25%) had a positive family history, 12.6% with associated thyroid disorders, 9.6% diabetes mellitus, 8.9% atopic dermatitis, 3.7% leukotrichia, and 2.2% alopecia areata. Sixty percent of patients had localized vitiligo, 37% generalized, 9.6% acrofacial, and 1.5% universal. The commonest site for the first vitiligo lesion was the face (28% of patients), whereas the commonest site at the time of diagnosis was the lower limb (51% of cases). The commonest topical treatment for localized vitiligo was tacrolimus (34.8%), whereas narrow band ultraviolet B (14%) had most commonly been prescribed for those with generalized vitiligo. Conclusions: The patients were predominantly females, with a large proportion having a positive family history. The mean age of onset of vitiligo in our study was 24.5 years. It was commonly associated with thyroid disorders. Localized vitiligo was the most prevalent type. (C) 2014 Production and hosting by Elsevier B.V
引用
收藏
页码:17 / 21
页数:5
相关论文
共 32 条
[1]   A survey of vitiligo management among dermatologists in Saudi Arabia [J].
AlGhamdi, K. M. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (11) :1282-1288
[2]  
Altaf H, 2010, DERMATOL ONLINE J, V6, P3
[3]  
Arycan O, 2008, ACTA DERMATOVEN ALP, V17, P129
[4]  
BEHL PN, 1971, INDIAN J DERMATOL, V17, P51
[5]  
Behl PN, 1994, INDIAN J DERMATOL VE, V60, P275
[6]   Pathophysiology of vitiligo [J].
Castanet, J ;
Ortonne, JP .
CLINICS IN DERMATOLOGY, 1997, 15 (06) :845-851
[7]  
DAS S K, 1985, Genetic Epidemiology, V2, P71
[8]  
Dave Shriya, 2002, Indian J Dermatol Venereol Leprol, V68, P323
[9]   Vitiligo: A part of a systemic autoimmune process [J].
Gopal, K. V. T. ;
Rao, G. Raghu Rama ;
Kumar, Y. Had Kishan ;
Rao, M. V. Appa ;
Vasudev, P. ;
Srikant .
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2007, 73 (03) :162-165
[10]   Topical tacrolimus therapy for vitiligio: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines [J].
Grimes, PE ;
Morris, R ;
Avaniss-Aghajani, E ;
Soriano, T ;
Meraz, M ;
Metzger, A .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (01) :52-61